DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 50+ Recurrent Glioblastoma companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
- DelveInsight’s Recurrent Glioblastoma Pipeline analysis depicts a robust space with 50+ Recurrent Glioblastoma companies working to develop 50+ pipeline treatment therapies.
- The leading Recurrent Glioblastoma Companies working in the market include Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation LLC, Istari Oncology Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix Inc., NanoPharmaceuticals LLC, Erasca Inc., Oblato Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology Inc., Chimerix, and others.
- Promising Recurrent Glioblastoma Pipeline Therapies in the various stages of development include ACT001, GX-I7, Bevacizumab, MTX110, Lomustine, TTAC-0001 and pembrolizumab combination, Chemotherapy, and others.
- December 2023: Jonsson Comprehensive Cancer Center announced a study of phase 2 clinical trials for Osimertinib. This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma.
- December 2023: Eli Lilly and Company announced a study of phase 2 clinical trials for LY2157299 monohydrate and Lomustine. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer.
- On June 2023, Genexine Inc. announced a study of phase 2 clinical trials for GX-17 and Bevacizumab. The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
- On May 2023, Biodexa Pharmaceuticals announced a study of phase 1 clinical trials for MTX110 and Lomustine. A study designed to assess the safety of MTX110 alone and in combination with lomustine for patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.
Request a sample and discover the recent advances in Recurrent Glioblastoma Treatment Drugs @ Recurrent Glioblastoma Pipeline Outlook Report
In the Recurrent Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Recurrent Glioblastoma Overview
Recurrent Glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission.
Find out more about Recurrent Glioblastoma Therapeutics Assessment @ Recurrent Glioblastoma Preclinical and Discovery Stage Products
Recurrent Glioblastoma Emerging Drugs Profile
- ASC40: Ascletis
- GX-I7: Genexine
- Olinvacimab: PharmAbcine
- VXM01: VAXIMM AG
Recurrent Glioblastoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Recurrent Glioblastoma. The Recurrent Glioblastoma companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Ascletis.
DelveInsight’s Recurrent Glioblastoma pipeline report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Recurrent Glioblastoma Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Learn more about the emerging Recurrent Glioblastoma Pipeline Therapies @ Recurrent Glioblastoma Clinical Trials Assessment
Scope of the Recurrent Glioblastoma Pipeline Report
- Coverage- Global
- Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation LLC, Istari Oncology Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix Inc., NanoPharmaceuticals LLC, Erasca Inc., Oblato Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology Inc., Chimerix, and others.
- Recurrent Glioblastoma Therapies- ACT001, GX-I7, Bevacizumab, MTX110, Lomustine, TTAC-0001 and pembrolizumab combination, Chemotherapy, and others
- Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for new drugs for Recurrent Glioblastoma Treatment, Visit @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Recurrent Glioblastoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ASC40: Ascletis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- GX-I7: Genexine
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- VXM01: VAXIMM AG
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Recurrent Glioblastoma Key Companies
- Recurrent Glioblastoma Key Products
- Recurrent Glioblastoma- Unmet Needs
- Recurrent Glioblastoma- Market Drivers and Barriers
- Recurrent Glioblastoma- Future Perspectives and Conclusion
- Recurrent Glioblastoma Analyst Views
- Recurrent Glioblastoma Key Companies
- Appendix
For further information on the Recurrent Glioblastoma Pipeline therapeutics, reach out to Recurrent Glioblastoma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market